| CTRI Number |
CTRI/2025/07/090763 [Registered on: 11/07/2025] Trial Registered Prospectively |
| Last Modified On: |
09/07/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Observational |
|
Type of Study
|
Cross Sectional Study |
| Study Design |
Other |
|
Public Title of Study
|
Usefulness of AFP, PIVKA - II and ASAP score in diagnosis of Hepatocellular Carcinoma and their correlation with disease severity. |
|
Scientific Title of Study
|
Diagnostic Utility of AFP, PIVKA-II, and ASAP Score in Hepatocellular Carcinoma (HCC): Correlation with Histopathological and Radiological Tumor Grading |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Ravi Singhal |
| Designation |
DNB resident |
| Affiliation |
Medanta Medicity Gurugram |
| Address |
Department of Biochemistry, Medanta-The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram
Gurgaon HARYANA 122001 India |
| Phone |
8076157043 |
| Fax |
|
| Email |
ravisinghal@hotmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Anuj Parkash |
| Designation |
Associate Director and Head of Department - Biochemistry |
| Affiliation |
Medanta Medicity Gurugram |
| Address |
Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram
Gurgaon HARYANA 122001 India |
| Phone |
9643001625 |
| Fax |
|
| Email |
anuj.parkash@medanta.org |
|
Details of Contact Person Public Query
|
| Name |
Dr Ravi Singhal |
| Designation |
DNB resident |
| Affiliation |
Medanta Medicity Gurugram |
| Address |
Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram
Gurgaon HARYANA 122001 India |
| Phone |
8076157043 |
| Fax |
|
| Email |
ravisinghal@hotmail.com |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
Medanta Medicity Gurugram |
| Address |
Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram, Haryana 122001 |
| Type of Sponsor |
Private hospital/clinic |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Ravi Singhal |
Medanta Medicity Gurgaon |
Medanta- The Medicity, CH Baktawar Singh Rd, Medicity, Islampur Colony, Sector 38, Gurugram, Haryana 122001 Gurgaon HARYANA |
8076157043
ravisinghal@hotmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Medanta Institutional Ethics Committee |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: C220||Liver cell carcinoma, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Nil |
Nil |
|
|
Inclusion Criteria
|
| Age From |
18.00 Year(s) |
| Age To |
90.00 Year(s) |
| Gender |
Both |
| Details |
Adults more than 18 years
Patients with newly diagnosed radiologically or histologically confirmed HCC.
Patients in which histopathological tumor grading has been done as per the WHO Grading system for Hepatocellular Carcinoma, radiological grading done as per on Li-RADS and severity (tumor staging/extent of disease) determined as per Barcelona Clinic Liver Cancer (BCLC) Staging.
|
|
| ExclusionCriteria |
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Not Applicable |
|
Primary Outcome
|
| Outcome |
TimePoints |
-Primary Objective – To determine the Diagnostic value of AFP, PIVKA – II, and combined ASAP score in diagnosis of Hepatocellular Carcinoma.
|
At end of the study, 12 months.
|
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
| -Secondary Objective – Correlation of AFP levels, PIVKA-II levels, & combined ASAP score to histopathological, radiological, & clinical tumor grading. |
At end of study 12 months. |
|
|
Target Sample Size
|
Total Sample Size="90" Sample Size from India="90"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
N/A |
|
Date of First Enrollment (India)
|
21/07/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Hepatocellular
carcinoma (HCC) is the most common primary malignancy of the liver and a
leading cause of cancer-related deaths worldwide. Its incidence is steadily
increasing due to the global rise in chronic liver diseases such as hepatitis B
and C, alcoholic liver disease, and metabolic dysfunction – associated
steatotic liver disease (MASLD). Early detection remains critical, as
30–40% of patients present at advanced stages with limited treatment options
and a 5-year survival rate below 20%.
Serum
alpha-fetoprotein (AFP), a glycoprotein elevated in 60–70% of HCC cases, has
traditionally been used for screening but suffers from poor sensitivity
(18–60%) and specificity (85–90%), particularly in early-stage tumours. For
instance, AFP fails to detect 80% of HCC nodules <3 cm, and its levels can
rise non-specifically during hepatic inflammation or regeneration.
In
recent years, des-gamma-carboxy prothrombin, also known as PIVKA-II (Protein
Induced by Vitamin K Antagonist-II), has emerged as a promising complementary
biomarker with better performance in certain clinical settings. Studies
have reported 81.55 % sensitivity and 86 % specificity at cutoff values of
43.47 mAU/mL. Unlike AFP, PIVKA-II levels correlate with tumour
aggressiveness and vascular invasion, making it valuable for monitoring
progression.
To
enhance diagnostic accuracy, composite scoring systems such as the ASAP
score—which integrates Age, Sex, AFP, and PIVKA-II—have been developed and
evaluated in various populations. These multiparametric tools may improve
early detection and allow risk stratification, but their clinical utility in
different ethnic and demographic groups, including the Indian population,
remains underexplored.
Moreover,
the correlation between biomarker levels and the histological grade or clinical
stage of HCC could provide valuable prognostic insights and support the
development of personalized therapeutic strategies .
This
study aims to compare the diagnostic efficacy of AFP, PIVKA-II, and the ASAP
score in the detection of HCC and to analyse their correlation with tumour
grade and severity in a population mix in Tertiary care Hospital, thereby
contributing to a more refined and personalized approach to HCC diagnosis. |